Typhoid medicine referance details
Reading File
Searching for comprehensive typhoid medicine reference details now.
search_medical_text
typhoid fever treatment antibiotics management
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 4861
search_medical_text
Salmonella typhi diagnosis clinical features complications
Bailey and Love's Short Practice of Surgery 28th Edition
Page 1387
GradeResponse
GradeResponse
Here is a comprehensive typhoid fever medicine reference:
Typhoid Fever — Medical Reference
Overview
Typhoid fever (enteric fever) is caused by Salmonella enterica serotype Typhi, and paratyphoid fever by S. Paratyphi A, B, or C. It is transmitted via the fecal-oral route, typically through contaminated food or water.
Clinical Features
| Phase | Timeline | Features |
|---|---|---|
| Incubation | 10–20 days | Asymptomatic |
| Week 1 | Onset | Fever (stepwise rise), headache, malaise, relative bradycardia |
| Week 2 | Progression | Abdominal pain/distension, diarrhea or constipation, splenomegaly, rose spots (abdominal vasculitic rash) |
| Week 3+ | Complications | Intestinal hemorrhage, perforation, paralytic ileus, cholecystitis |
(Bailey & Love's Surgery, 28th Ed., p. 1387)
Diagnosis
- Blood culture — gold standard (positive in ~60–80% in week 1)
- Bone marrow culture — highest sensitivity (~90%), even after antibiotics started
- Stool/urine culture — positive in later weeks
- Widal test — suggestive but low specificity; rising titers more meaningful
- CBC: relative leukopenia, anemia, thrombocytopenia
- LFTs: mildly elevated transaminases
Antibiotic Treatment
(Harrison's Principles of Internal Medicine, 21st Ed., p. 4861)
First-Line Agents
| Antibiotic | Dose | Duration | Notes |
|---|---|---|---|
| Ceftriaxone | 2–3 g IV/IM once daily | 10–14 days | Drug of choice in endemic regions (India, Nepal, Africa) with DSC/MDR strains |
| Azithromycin | 500 mg–1 g orally daily | 7 days | Preferred for uncomplicated typhoid; good oral bioavailability |
| Ciprofloxacin | 500 mg orally twice daily OR 400 mg IV twice daily | 10–14 days | Only for confirmed quinolone-susceptible strains |
| Ofloxacin | 400 mg orally twice daily | 7–10 days | Effective for quinolone-susceptible strains |
⚠️ Important: Fluoroquinolones should NOT be used empirically in the Indian subcontinent, Nepal, or parts of Africa due to high prevalence of strains with decreased susceptibility to ciprofloxacin (MIC >0.125 µg/mL). (Harrison's, p. 4861)
Multidrug-Resistant (MDR) Typhoid (resistant to Ampicillin, Chloramphenicol, Co-trimoxazole)
| Antibiotic | Dose | Duration |
|---|---|---|
| Ceftriaxone | 2–3 g IV daily | 10–14 days |
| Azithromycin | 1 g orally daily | 5–7 days |
Extensively Drug-Resistant (XDR) Typhoid (also resistant to fluoroquinolones + 3rd-gen cephalosporins)
| Antibiotic | Dose | Notes |
|---|---|---|
| Meropenem | 1 g IV every 8 hours | Drug of choice for XDR |
| Azithromycin | 1 g orally daily | If susceptible |
Older Agents (for Fully Susceptible Strains Only)
| Antibiotic | Dose | Duration |
|---|---|---|
| Chloramphenicol | 500 mg orally 4× daily | 14 days |
| Ampicillin | 750–1000 mg orally 4× daily | 14 days |
| Co-trimoxazole (TMP-SMX) | 160/800 mg orally twice daily | 14 days |
Special Populations
| Group | Recommendation |
|---|---|
| Children | Ceftriaxone 60 mg/kg/day IV or Azithromycin 20 mg/kg/day orally |
| Pregnant women | Ceftriaxone preferred; avoid fluoroquinolones and chloramphenicol |
| Severe/complicated typhoid | IV Ceftriaxone + Dexamethasone (for altered consciousness or shock) |
Surgical Complications & Management
(Bailey & Love's, p. 1387)
- Intestinal perforation — emergency laparotomy; most common in 3rd week
- GI hemorrhage — transfusion + surgical intervention if uncontrolled
- Paralytic ileus — conservative (NG suction, IV fluids)
- Cholecystitis — cholecystectomy may be needed (typhoid carriers)
Chronic Carriage
- Defined as fecal excretion of S. Typhi >1 year
- Treatment: Ciprofloxacin 750 mg twice daily × 4 weeks (if quinolone-sensitive) or Ampicillin + Probenecid
- Cholecystectomy considered in gallbladder carriers unresponsive to antibiotics
Vaccination
| Vaccine | Type | Route | Duration |
|---|---|---|---|
| Ty21a (Vivotif) | Live attenuated oral | Oral | 5–7 years |
| Vi polysaccharide (Typhim Vi) | Injectable | IM | ~3 years |
| Vi-conjugate (Typbar-TCV) | Conjugate injectable | IM | Longer; preferred in children ≥6 months |
Key Takeaway
- Azithromycin or Ceftriaxone are the current empirical treatments of choice in most endemic regions.
- Always check local susceptibility patterns before prescribing fluoroquinolones.
- Prompt treatment reduces mortality to <1%. (Harrison's, 21st Ed., p. 4861)
This is a shared conversation. Sign in to Orris to start your own chat.